New drug BL-B01D1 tested in tiny early trial for tough cancers

NCT ID NCT05393427

Ongoing Disease control Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study tests a new drug called BL-B01D1 in people with advanced urinary or other solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and get a first look at whether it might shrink tumors. Only 4 participants are enrolled, so results are very preliminary.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: BL-B01D1 (a drug given by IV infusion)
What this could lead to: If it works, this could point toward a new treatment option for advanced urinary and other solid tumors that have not responded to standard therapies.
What could go wrong: This is a very early Phase 1 trial with only 4 participants, so it is primarily checking safety and dosing. It is too small and early to know if the drug will be effective or have manageable side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED OR METASTATIC URINARY TUMORS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

malignant urinary system neoplasm neoplasm renal cell carcinoma Urinary Bladder Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LOCALLY ADVANCED OR METASTATIC URINARY TUMORS OTHER SOLID TUMORS

Contacts and locations

Locations

Beijing Cancer Hospital

Beijing, Beijing Municipality, 100142, China
Chongqing University Cancer Hospital

Chongqing, Chongqing Municipality, China
Peking University First Hospital

Beijing, Beijing Municipality, China
West China Hospital, Sichuan University

Chengdu, Sichuan, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.